14 completed, 4 terminated, 2 recruiting, 1 active not recruiting. 23 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 23 | Completed 14, Terminated 4, Recruiting 2, Active not recruiting 1, Not yet recruiting 1, Suspended 1 |
| Phase 2 | 5 | Completed 3, Not yet recruiting 1, Terminated 1 |
Follow Tinnitus: new trials by email Literature Review of Tinnitus trials Research Report on Tinnitus
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| SPI-1005 for the Treatment of Meniere's Disease (Open Label) Ebselen - Meniere's Disease, Ménière's Disease | Phase 3 | Active not recruiting | Sound Pharmaceuticals, Incorporated | 200 | 2025-10-29 | 2026-07-13 |
| Efficacy and Safety of Isosorbide Oral Solution in Patients With Meniere's Disease Isosorbide oral solution, Placebo - Meniere´s Disease | Phase 2 / Phase 3 | Not yet recruiting | Lunan Better Pharmaceutical Co., LTD. | 234 | 2024-12-30 | 2025-01-09 |
| Oto Smartphone App in Treating Tinnitus Amongst Adult Patients Compared with Standard Talking Therapies Oto Smartphone Application (Oto Health Ltd), Tinnitus Retraining Therapy (TRT) - Tinnitus | Phase 3 | Recruiting | East and North Hertfordshire NHS Trust | 160 | 2024-06-20 | 2024-10-02 |
| The Effecttiveness of Intratympanic Methylprednisolon Injections Compared to Placebo in the Treatment of Vertigo Attacks in Meniere's Disease Methylprednisolon, Placebo - Meniere Disease | Phase 3 | Recruiting | Leiden University Medical Center | 148 | 2023-10-01 | 2023-12-04 |
| SPI-1005 for the Treatment of Meniere's Disease Ebselen, Placebo - Meniere Disease, Ménière | Phase 3 | Completed | Sound Pharmaceuticals, Incorporated | 220 | 2022-08-02 | 2026-07-23 |
| High Dose Oxytocin Nasal Spray for Treatment of Tinnitus Oxytocin, Placebo nasal spray - Tinnitus | Phase 3 | Terminated | NYU Langone Health | 33 | 2020-01-15 | 2022-10-05 |
| AM-101 in the Treatment of Post-Acute Tinnitus 1 AM-101 - Tinnitus | Phase 3 | Completed | Auris Medical, Inc. | 260 | 2014-06-01 | 2018-05-16 |
| AM-101 in the Treatment of Post-Acute Tinnitus 2 AM-101 - Tinnitus | Phase 3 | Completed | Auris Medical AG | 487 | 2014-06-01 | 2023-09-14 |
| AM-101 in the Treatment of Acute Tinnitus 2 AM-101, Placebo - Tinnitus | Phase 3 | Completed | Auris Medical, Inc. | 343 | 2014-02-01 | 2018-05-29 |
| AM-101 in the Treatment of Acute Tinnitus 3 AM-101, Placebo - Tinnitus | Phase 3 | Completed | Auris Medical AG | 893 | 2014-01-01 | 2023-09-14 |
| Evaluation of the CR Neuromodulation Treatment for Tinnitus CR Neuromodulation, Tinnitus masking - Tinnitus | Phase 2 / Phase 3 | Completed | Nottingham University Hospitals NHS Trust | 100 | 2012-08-01 | 2016-08-22 |
| Cognitive Training for Firefighters With Tinnitus Brain Fitness Program - Tinnitus - Tinnitus | Phase 3 | Completed | Washington University School of Medicine | 60 | 2012-03-01 | 2014-05-09 |
| Famvir for Treatment of Hearing in Unilateral Meniere's Disease Famciclovir, Placebo - Meniere's Disease | Phase 3 | Terminated | House Research Institute | 11 | 2011-12-01 | 2021-04-19 |
| Tinnitus Retraining Therapy Trial Conventional sound generator (SG), Placebo sound generator (placebo SG), Standard of Care (SC) - Subjective Tinnitus | Phase 3 | Completed | Johns Hopkins Bloomberg School of Public Health | 151 | 2011-07-01 | 2018-11-21 |
| A Trial of Magnesium Dependent Tinnitus Magnesium, Placebo - Tinnitus | Phase 3 | Completed | Mayo Clinic | 38 | 2011-07-01 | 2015-04-30 |
| Caroverin and Inner Ear Diseases Caroverin - Tinnitus | Phase 3 | Suspended | Phafag AG | 170 | 2011-01-01 | 2015-08-07 |
| Idiopathic Intracranial Hypertension Treatment Trial Acetazolamide, Placebo, Formal weight loss counselling program - Idiopathic Intracranial Hypertension | Phase 2 / Phase 3 | Completed | St. Luke's-Roosevelt Hospital Center | 165 | 2010-01-01 | 2018-12-12 |
| Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus Neramexane mesylate, Placebo - Subjective Tinnitus | Phase 3 | Completed | Merz Pharmaceuticals GmbH | 455 | 2009-09-01 | 2012-11-28 |
| Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus Neramexane mesylate - Subjective Tinnitus | Phase 3 | Terminated | Merz Pharmaceuticals GmbH | 821 | 2009-01-01 | 2012-11-28 |
| Efficacy, Safety and Tolerability of Neramexane in Comparison to Placebo in Patients With Subjective Tinnitus Neramexane mesylate, Placebo - Subjective Tinnitus | Phase 3 | Completed | Merz Pharmaceuticals GmbH | 400 | 2008-11-01 | 2010-07-01 |
Showing 20 of 23. Sign in to see all of them.
Hearing Loss (6) · Meniere Disease (4) · Dizziness (3) · Vertigo (3) · Blast Injuries (1) · Diplopia (1) · Headache (1) · Hearing Disorders (1) · Hearing Loss, Sudden (1) · Hyperacusis (1) · Obesity (1) · Papilledema (1) · Presbycusis (1) · Pseudotumor Cerebri (1)
Ear Diseases (23) · Nervous System Diseases (23) · Neurologic Manifestations (23) · Otorhinolaryngologic Diseases (23) · Pathological Conditions, Signs and Symptoms (23) · Sensation Disorders (23) · Signs and Symptoms (23) · Hearing Disorders (22) · Endolymphatic Hydrops (4) · Labyrinth Diseases (4) · Vestibular Diseases (3) · Barotrauma (1) · Body Weight (1) · Brain Diseases (1) · Central Nervous System Diseases (1)
PDCD5 protein, rat (4) · ebselen (2) · Acetaminophen (1) · Acetazolamide (1) · Aspirin (1) · Codeine (1) · Directive Counseling (1) · Famciclovir (1) · Gabapentin (1) · Ibuprofen (1) · Isosorbide (1) · Magnesium (1) · Methylprednisolone (1) · Naproxen (1) · Oxytocin (1)
Merz Pharmaceuticals GmbH (4) · Auris Medical AG (2) · Auris Medical, Inc. (2) · Sound Pharmaceuticals, Incorporated (2) · Washington University School of Medicine (2) · East and North Hertfordshire NHS Trust (1) · House Research Institute (1) · Johns Hopkins Bloomberg School of Public Health (1) · Leiden University Medical Center (1) · Lunan Better Pharmaceutical Co., LTD. (1) · Mayo Clinic (1) · NYU Langone Health (1) · Nottingham University Hospitals NHS Trust (1) · Phafag AG (1) · St. Luke's-Roosevelt Hospital Center (1)
United States (11) · Germany (5) · Austria (4) · United Kingdom (4) · France (3) · Netherlands (3) · Belgium (2) · Brazil (2) · Czechia (2) · Mexico (2) · Poland (2) · Portugal (2) · South Africa (2) · Spain (2) · Canada (1)
Jay F Piccirillo, MD (2) · C. Craig Formby, PhD (1) · David McAlpine, PhD (1) · Deborah A Hall, PhD (1) · Derek J Hoare, PhD (1) · Emmanuel Cuny, MD (1) · Jennifer Derebery, MD (1) · Lawrence Newman, MD (1) · Michael Cevette, PhD (1) · Michael Wall, MD (1) · Roberta W Scherer, PhD (1) · Wolfgang Elsaesser, Dr. (1)
PMID 17438255, PMID 24756302, PMID 24756514, PMID 24781936, PMID 25017670, PMID 25370510, PMID 25370513, PMID 26024112, PMID 26335066, PMID 26618282, PMID 26778344, PMID 26934136, PMID 27694262, PMID 28114646, PMID 28130349, PMID 28492874, PMID 28608739, PMID 29792074, PMID 31120533, PMID 32703244, PMID 35073492, PMID 35326273, PMID 39209781
2009 (2), 2008 (1), R01DC006253 (1), U01DC007422 (1), U10EY017281 (1), U10EY017387 (1)